ArticleJournal of the American Academy of Child and Adolescent Psychiatry2026
A Prospective Birth Cohort Study on the Association Between Cord Blood Acylcarnitine Profile and Childhood Risk of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder.
Article in Journal of the American Academy of Child and Adolescent Psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveMitochondria have been implicated in the etiology of autism spectrum disorder (ASD), but evidence for attention-deficit/hyperactivity disorder (ADHD) remains limited. Given the early onset of both ASD and ADHD and high degree of comorbidity, this study sought to examine the prospective association of 20 acylcarnitines in cord blood-a group of metabolites involved in mitochondrial fatty acid metabolism-with childhood risk of ASD, ADHD, and other neurodevelopmental disorders (NDDs).
methodThis study includes 995 children (55% male participants, 58% non-Hispanic Black) from the Boston Birth Cohort. Acylcarnitines in cord blood were profiled using liquid chromatography-tandem mass spectrometry. Logistic regressions examined individual acylcarnitines and their 3 principal components (PC) in relation to childhood ADHD (n = 285), ASD (n = 86), and other NDDs (n = 246) compared to those in typically developing children (n = 378), with adjustment of maternal and child characteristics.
resultsChildren with higher levels of short-chain and long-chain acylcarnitines in cord blood (including C2, C3, C3-DC-CH3, C14, C16, C18, and C18:1) had a greater risk of childhood ADHD. The highest tertile of long-chain acylcarnitine PC scores was associated with 1.98 times odds of ADHD (adjusted OR = 1.98; 95% CI = 1.29-3.06), compared to the lowest tertile. A 1-unit increase in medium-chain PC scores was associated with 1.38 times odds of ASD (adjusted OR = 1.38; 95% CI = 1.01-1.90).
conclusionThis prospective birth cohort study found that cord blood acylcarnitines were associated with childhood risk of ASD, ADHD, and other NDDs, highlighting the important role of mitochondrial fatty acid metabolism in NDDs and potential targets for investigation and interventions. PLAIN LANGUAGE SUMMARY: Altered mitochondrial function has been associated with autism spectrum disorder (ASD), but evidence for attention-deficit/hyperactivity disorder (ADHD) remains limited. This prospective study of a racially diverse birth cohort (N = 995) found associations between increased levels of cord blood acylcarnitines-a group of metabolites involved in mitochondrial fatty acid metabolism-and a higher likelihood of ADHD and ASD diagnosis. These findings highlight the potential role of mitochondrial fatty acid metabolism in neurodevelopmental disorders and potential targets for investigation and interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.